All In MedTech

FDA Clearance Tracker · P120023

KAMRA INLAY

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Apr 17, 2015 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Apr 17, 2015

Approval withdrawn

Time to decision

856 days

Received Dec 12, 2012. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P120023
Device name
KAMRA INLAY
Applicant
Corneagen
Applicant location
Seattle, WA
Received
Dec 12, 2012
Decided
Apr 17, 2015
Decision
Approval withdrawn
Supplements
4 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LQE

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE KAMRA INLAY. THE KAMRA INLAY IS INDICATED FOR INTRASTROMAL CORNEAL IMPLANTATION TO IMPROVE NEAR VISION BY EXTENDING THE DEPTH OF FOCUS IN THE NON-DOMINANT EYE OF PHAKIC, PRESBYOPIC PATIENTS BETWEEN THE AGES OF 45 AND 60 YEARS OLD WHO HAVE CYCLOPLEGIC REFRACTIVE SPHERICAL EQUIVALENT OF +0.50 D TO -0.75 D WITH LESS THAN OR EQUAL TO 0.75 D OF REFRACTIVECYLINDER, WHO DO NOT REQUIRE GLASSES OR CONTACT LENSES FOR CLEAR DISTANCE VISION, AND WHO REQUIRE NEAR CORRECTION OF +1.00 D TO +2.50 D OF READING ADD.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LQE. The earliest in FDA's data is P980031, decided Apr 9, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Corneagen

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.